News and Trends 21 Feb 2017 New Immunotherapy Candidate receives FDA Fast Track Designation Cell Medica’s Orphan Drug CMD-003 has received fast track designation by the FDA to advance immunotherapy of patients with Epstein Bar Virus (EBV)-associated malignancies. The FDA’s fast track designation has been designed to facilitate and accelerate the development of drugs which fill a major unmet medical need. It has now been granted to Cell Medica’s lead EBV immunotherapy […] February 21, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 20 Feb 2017 Alphamer Technology gets Seed Fundraising to Fight Antibiotic Resistance Centauri Therapeutics has raised £1.2M in the second part of its seed round, which will be directed at bringing its first alphamer to the preclinical stage. Centauri Therapeutics, a young British biotech, is developing alphamer technology to fights infectious disease and cancer. Today, the company has announced the addition of £1.2M from existing and new investors […] February 20, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 20 Feb 2017 Investment CEO shares Tips for Academics on Succeeding in Business With decades of experience, the CEO of Touchstone Innovations tells us about funding the development of academic projects into commercialized products Formerly known as Imperial Innovations, the investing arm of Imperial College in London has since morphed into Touchstone Innovations, an UK technology commercialization and investment company with the same core mission in bridging the gap […] February 20, 2017 - 7 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 18 Feb 2017 Microorganisms in the Library: Bringing Centuries-Old Books to Life Sarah Craske describes herself as a “British artist, without category.” Her work, at the intersection of art and science, revolves around the development of her own discipline: Biological Hermeneutics. Hermeneutics refers to the interpretation of texts, a term commonly used regarding the bible or philosophy. Craske translates the concept to biology by exploring the role […] February 18, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 Feb 2017 UPDATE: British Biotech Investment Company goes Public with €117M UPDATE (17/02/2017): Arix Bioscience announced that it has successfully raised £100M (€117) in an oversubscribed IPO on the London Stock Exchange. Originally published on 02/02/2017 Arix Bioscience is getting ready for an IPO that could reach up to €117M (£100M). The funds will be directed at small life science companies. Arix Bioscience is a ‘global healthcare and life […] February 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Feb 2017 British Scientists Discover how Deadly Bacteria Survive a Last-Line Antibiotic Researchers from the UK and Australia have described for the first time the detailed molecular mechanisms behind last-line antibiotic resistance. A month ago, the news of a woman who died of an infection with a bacteria resistant to all 26 antibiotics available in the US traveled the world. The bacterial strain responsible, Klebsiella pneumoniae, is one […] February 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Feb 2017 The Patent Office has Spoken: What does it Mean for CRISPR in Europe? The US Patent Office has ruled that the Broad Institute’s CRISPR patents do not interfere with those from UC Berkeley. While this might sound like everybody wins, it’s actually a loss for Charpentier and the CRISPR Therapeutics team. CRISPR has been hailed as the ‘scientific discovery of the century’. This molecular technique could be used […] February 16, 2017 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 14 Feb 2017 Dual HIV Therapy: GSK and Gilead Battle over Whose Drug is the Best GSK announced Phase III results for dolutegravir, which could reduce triple HIV therapy down to two drugs, but Gilead is trying to prove that its candidate bictegravir is better. GSK and Gilead have announced they will present detailed data backing their candidates for a dual HIV therapy. The battlefield will be the Annual Conference on Retroviruses […] February 14, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 13 Feb 2017 Biotech from the Bermuda Islands Brings Good News for Dementia Patients Axovant Sciences has announced positive preliminary results from a Phase II trial directed at reducing hallucinations in patients with dementia. Axovant Sciences is a biotech located in Bermuda, a British tropical island in the Atlantic ocean. From there, the company develops drugs against dementia. The company was founded by young biotech entrepreneur Vivek Ramaswamy, which has […] February 13, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 13 Feb 2017 To the Rescue: A Final Phase III Success for Post-Operative Nausea The dopamine antagonist Baremsis is on its way to FDA approval for the treatment and prophylaxis of post-operative nausea & vomiting, after succeeding in a final phase III study. Acacia Pharma, one of our Cambridge top 15 biotechs, is repurposing marketed drugs to provide supportive treatments for post-surgical or cancer patients. Their lead project, Baremsis, is a dopamine antagonist, which Acacia is […] February 13, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
More News! 11 Feb 2017 This Musician Plays Piano Duets with a Microorganism Eduardo Miranda researches, composes and performs contemporary music at the interface of biology, computing and the human mind. Eduardo Miranda, Professor of Computer Music at Plymouth University, is the first person to ever compose and perform a piano piece for a human and a microorganism. To allow the tiny creature to play with him, Miranda […] February 11, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 9 Feb 2017 After its First Success, the Virtual Biotech Team is Back at it Again SuperX has raised €10.3M ($11M) in Series A from Medicxi and J&J Innovation to develop anticoagulant antibodies for stroke and heart attacks. The team behind XO1, which was acquired by J&J’s Janssen back in 2015, is repeating the whole process again. Their new company, SuperX, is also focused on the discovery of anticoagulant antibodies to treat […] February 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email